We have received text from H.R. 7050: Homeopathic Drug Product Safety, Quality, and Transparency Act. This bill was received on 2026-01-14, and currently has 2 cosponsors.
Here is a short summary of the bill:
The Homeopathic Drug Product Safety, Quality, and Transparency Act is designed to amend current legislation related to homeopathic drug products under the Federal Food, Drug, and Cosmetic Act. The aim of the bill is to establish clear safety, quality, and transparency standards that homeopathic products must meet. Here are the key provisions of the bill:
Purpose
The bill emphasizes the importance of homeopathic medicines for consumers and seeks to create a regulatory pathway that allows the continued access to safe homeopathic drug products. It aims to ensure that while the federal government protects against harmful products, it does not create unnecessary barriers that would limit access to safe homeopathic remedies.
Definitions
- Homeopathic Drug Product: A drug that contains one or more homeopathic ingredients and no other active ingredients.
- Homeopathic Ingredient: An ingredient that is listed in the Homeopathic Pharmacopoeia of the United States or is prepared according to set standards for homeopathy.
Safety, Quality, and Transparency Requirements
The bill outlines specific provisions for homeopathic drug products:
- Current regulations outside this section will not apply unless they align with the new homeopathic standards.
- Homeopathic products must not be adulterated, which means they must meet the established safety and quality standards.
- Manufacturers can petition for exemptions or alternative standards, but any changes must ensure product safety.
- Testing requirements are specified, including the need for testing to ensure the absence of harmful contaminants.
Labeling and Misbranding
The bill provides detailed requirements for labeling homeopathic drug products:
- The word "homeopathic" cannot be included unless the product meets the definitions stipulated by the new regulations.
- Labeling must include the purpose or indications for use based on recognized sources.
- Products need to clearly state that their uses have not been evaluated by the FDA.
Exemption from Premarket Approval
The bill states that homeopathic drug products do not require premarket approval, easing the pathway to market for these products.
Homeopathic Drug Product Advisory Committee
The legislation proposes the establishment of a committee to advise on the regulation of homeopathic drug products. This committee will include various representatives from consumer and practitioner backgrounds, aiming to offer a balanced perspective. The committee will meet regularly to discuss homeopathy-related issues and can also investigate adverse events related to homeopathic products.
Non-Preemption of State Laws
The bill clarifies that it does not interfere with state laws regarding the practice of homeopathy, thus maintaining state authority in this area.
Other Provisions
The bill aims to withdraw previous guidance concerning homeopathic drug products that may be inconsistent with the new regulations. It also includes language regarding the burden of proof in legal contexts related to violations of these provisions.
Relevant Companies
- UNFI (United Natural Foods, Inc.): As a distributor of natural and organic foods, including homeopathic products, UNFI may face shifts in the market and regulatory requirements regarding the distribution and labeling of homeopathic remedies.
- TARO (Taro Pharmaceutical Industries Ltd): As a manufacturer of topical medications, Taro may see changes in the production and regulation of its homeopathic offerings.
Representative Pete Sessions Bill Proposals
Here are some bills which have recently been proposed by Representative Pete Sessions:
- H.R.7050: To amend the Federal Food, Drug, and Cosmetic Act with respect to homeopathic drug products, and for other purposes.
- H.R.6412: Independence Investment Fund Act
- H.R.5125: District of Columbia Judicial Nominations Reform Act of 2025
- H.R.4863: Fairness for Khobar Act of 2025
- H.R.3420: Words Matter Act of 2025
- H.R.3417: Websites and Software Applications Accessibility Act of 2025
You can track bills proposed by Representative Pete Sessions on Quiver Quantitative's politician page for Sessions.
Representative Pete Sessions Net Worth
Quiver Quantitative estimates that Representative Pete Sessions is worth $9.8M, as of January 30th, 2026. This is the 107th highest net worth in Congress, per our live estimates.
Sessions has approximately $3.3M invested in publicly traded assets which Quiver is able to track live.
You can track Representative Pete Sessions's net worth on Quiver Quantitative's politician page for Sessions.
Representative Pete Sessions Stock Trading
We have data on up to $17.4M of trades from Representative Pete Sessions, which we parsed from STOCK Act filings. Some of the largest trades include:
- A October 31st, 2023 sale of up to $500K of $BUI. The stock has risen 42.11% since then.
- A September 10th, 2021 sale of up to $250K of $AAPL. The stock has risen 73.38% since then.
- A September 10th, 2021 sale of up to $250K of $JPM. The stock has risen 94.73% since then.
- A October 31st, 2023 sale of up to $250K of $PG. The stock has fallen 0.09% since then.
- A October 31st, 2023 sale of up to $250K of $LMT. The stock has risen 36.92% since then.
You can track Representative Pete Sessions's stock trading on Quiver Quantitative's politician page for Sessions.
2026 Texas's 17th Congressional District Election
There has been approximately $1,148,098 of spending in Texas's 17th congressional district elections over the last two years, per our estimates.
The rating for this race is currently "Solid R".
You can track this election on our matchup page for the 2026 Texas's 17th congressional district election.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
